AB0421 MANAGEMENT OF ULCERATION IN SYSTEMIC SCLEROSIS BY A SPECIALIST PODIATURE SERVICE: A CASE SERIES

L. Parker1, R. Field2, J. Marks1. 1University Hospitals Dorset NHS Foundation Trust, Rheumatology Department, Christchurch, United Kingdom; 2University Hospitals Dorset NHS Foundation Trust, Rheumatology Department, Christchurch, United Kingdom

Background: Systemic sclerosis is a chronic disorder characterised by diffuse fibrosis and vascular abnormalities in the skin and major organs. Digital ulceration is a common complication, often resulting in patient disability. These ulcers can form through a variety of processes and management should be tailored according to aetiology. In Dorset, the specialist podiatory service has created a unique facility for optimal wound care in the setting of digital ulceration.

Objectives: In this case series, we outline podiatric management of 4 common causes of digital ulceration in systemic sclerosis.

Methods: Tissue ischemia, infection, micro-trauma and calcinosis were identified as four major contributory factors resulting in ulceration or delayed wound healing. Four cases exemplifying management of each different contributory factor were identified and their case notes reviewed in order to extract clinically relevant data and images.

Results: Case 1 illustrates treatment of ischaemic tissue injury to promote earlier healing, using careful wound care, debridement under local anaesthetic and low-level laser therapy.

Case 2 illustrates the importance of identifying repeated micro-trauma as a contributing factor to non-healing ulceration.

Case 3 demonstrates how surgical debridement or removal of the subcutaneous calcinosis in an outpatient setting can be a useful adjunct in encouraging ulcer healing.

Case 4 illustrates the complexity of correctly identifying infection in the setting of ulceration, with prompt management promoting wound healing.

Conclusion: The pathophysiology of ischaemic tissue damage in scleroderma is complex and can reflect a broad range of vascular pathologies, often occurring concurrently including vasospasm, macrovascular disease and microvascular disease leading to digital ulceration. Rapid identification of which processes are driving the ischaemia is critical in targeting therapy to the affected individual. A local podiatory service with expertise in management of tissue-related complications of systemic sclerosis is invaluable in promoting wound healing and preventing further complications.

REFERENCES:


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1276

AB0422 DIAGNOSTIC PERFORMANCE OF THE ACR/EULAR 2013 CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN A ROUTINE CARE SETTING

M. T. Schiaffino1, B. Serrano-Benavente2, M. Di Natale1, K. Carpio3, J. Martinez-Barrio4, P. Sanchez-Mateos1, J. M. Alvaro-Gracia5, I. Castrejon Fernandez6, 1Hospital Gregorio Maranon, Immunology, Madrid, Spain; 2Hospital Gregorio Maranon, Rheumatology, Madrid, Spain; 3Hospital Gregorio Maranon, Immunology, Madrid, Spain; 2Hospital Gregorio Maranon, Rheumatology, Madrid, Spain

Background: An ACR/EULAR task force released new criteria in 2013 to classify patients with systemic sclerosis (SSc). The pathophysiology of ischaemic tissue damage in scleroderma is complex and can reflect a broad range of vascular pathologies, often occurring concurrently including vasospasm, macrovascular disease and microvascular disease leading to digital ulceration. Rapid identification of which processes are driving the ischaemia is critical in targeting therapy to the affected individual. A local podiatory service with expertise in management of tissue-related complications of systemic sclerosis is invaluable in promoting wound healing and preventing further complications.

Methods: Tissue ischemia, infection, micro-trauma and calcinosis were identified as four major contributory factors resulting in ulceration or delayed wound healing. Four cases exemplifying management of each different contributory factor were identified and their case notes reviewed in order to extract clinically relevant data and images.

Results: Case 1 illustrates treatment of ischaemic tissue injury to promote earlier healing, using careful wound care, debridement under local anaesthetic and low-level laser therapy.

Case 2 illustrates the importance of identifying repeated micro-trauma as a contributing factor to non-healing ulceration.

Case 3 demonstrates how surgical debridement or removal of the subcutaneous calcinosis in an outpatient setting can be a useful adjunct in encouraging ulcer healing.

Case 4 illustrates the complexity of correctly identifying infection in the setting of ulceration, with prompt management promoting wound healing.

Conclusion: The pathophysiology of ischaemic tissue damage in scleroderma is complex and can reflect a broad range of vascular pathologies, often occurring concurrently including vasospasm, macrovascular disease and microvascular disease leading to digital ulceration. Rapid identification of which processes are driving the ischaemia is critical in targeting therapy to the affected individual. A local podiatory service with expertise in management of tissue-related complications of systemic sclerosis is invaluable in promoting wound healing and preventing further complications.

REFERENCES:


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1318

AB0423 SAFETY AND TOLERABILITY OF RITUXIMAB IN THE TREATMENT OF SYSTEMIC SCLEROSIS: LONG-TERM FOLLOW-UP

L. Garzano1, L. P. Ananyeva2, O. Koneva3, O. Desinova1, O. Ovsyannikova1, M. Starovoytova1, R. Shayakhmetova1, S. Glukhova1, 1VA Nasonova Research Institute of Rheumatology, Laboratory of Microrcirculation and Inflammation, Moscow, Russian Federation; 2VA Nasonova Research Institute of Rheumatology, Educational and Methodical Department, Moscow, Russian Federation

Background: Rituximab (RTX) has been used for the treatment of systemic sclerosis (SSc) for a long time, but data on tolerance and long-term adverse events (AE) are insufficient.

Objectives: To assess the tolerability and safety of RTX in the patients (pts) with SSc in long-term prospective follow-up.

Methods: Data on the safety and tolerability of RTX were evaluated in 149 SSc pts who received at least one RTX infusion in a long-term open-label prospective observational study. The mean age was 48±13.5 years (17-74), women - 122 (82%), diffuse cutaneous subset of the disease had 52%, limited-37% and overlap-11%.

Table 1. Demographic data and ACR/EULAR SSc classification criteria of SSc patients and controls.

<table>
<thead>
<tr>
<th></th>
<th>Cases-SSc, n= 130</th>
<th>Controls, n= 130</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD)</td>
<td>62.4 (16.0)</td>
<td>61.3 (14.8)</td>
<td>0.58</td>
</tr>
<tr>
<td>Female, %</td>
<td>90.5</td>
<td>90.8</td>
<td>0.92</td>
</tr>
<tr>
<td>Disease duration from onset of symptoms, mean (SD)</td>
<td>75 (6.4)</td>
<td>78 (6.7)</td>
<td>0.73</td>
</tr>
<tr>
<td>% Patients with individual ACR/EULAR 2013 Criteria Items</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin thickening</td>
<td>15.8</td>
<td>0.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sclerodacty</td>
<td>45.5</td>
<td>6.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Puffy fingers</td>
<td>27.7</td>
<td>1.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Digital tip ulcers</td>
<td>30.2</td>
<td>5.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Finger tip pitting scars</td>
<td>18.8</td>
<td>4.6</td>
<td>0.001</td>
</tr>
<tr>
<td>Telangiectasia</td>
<td>51.5</td>
<td>6.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Abnormal nailfold capillaries</td>
<td>79.4</td>
<td>0.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Pulmonary Arterial Hypertension</td>
<td>16.3</td>
<td>3.8</td>
<td>0.001</td>
</tr>
<tr>
<td>Pulmonary fibrosis</td>
<td>18.8</td>
<td>6.2</td>
<td>0.002</td>
</tr>
<tr>
<td>Raynaud’s phenomenon</td>
<td>90.7</td>
<td>66.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Anticentromere antibody</td>
<td>60.7</td>
<td>18.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Scl70</td>
<td>12.0</td>
<td>0</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Total Score</td>
<td>12.5 (4.8)</td>
<td>3.4 (2.9)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Figure 1. ROC curve for global score of the ACR/EULAR2013 SSc classification criteria.

Conclusion: The ACR/EULAR 2013 criteria showed good diagnostic properties in this cohort reflecting daily practice. Individual items showing the highest discriminatory capacity were abnormal capillaroscopy, telangiectasia and anticentromere antibody positivity.

REFERENCES:


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1318
The mean disease duration was 6.4±5.8 years (0.5-30). The observation period was 12 years. All pts received prednisolone at a dose of 11.7±4.9mg/day, and 73 patients (49%) received immunosuppressants at inclusion. The indications for the appointment of RTX were ineffectiveness or impossibility of standard therapy and a severe course of the disease with high activity and unfavorable prognosis factors. AE were assessed and recorded by a physician at a hospital immediately after the infusion of RTX, then by patient reported outcome during the observation period. Severe AE were defined as those that required hospitalization for more than 24 hours, exacerbation of the disease requiring therapy, malignancies, life-threatening situations. All causes of death were considered, regardless of treatment.

Results: The mean follow-up period after the first infusion of RTX was 5.6±2.6 years [834.4 patient-years (PY)]. Pts received a mean of 3.4 courses of RTX (1-10). The cumulative mean dose of RTX was 3.2±2.4 gr (0.5-11). AE were reported in 77 patients (52%), the overall frequency of AE was 9.3/100 PY (95% Confidence Interval (CI) 8-11). The highest frequency of all AE was observed in the first 2-6 months after the first infusion of RTX, however these were mainly mild AE (71%). There was a decrease of AE in the follow-up period (3.4/100 PY, 95% CI 2.4-4.9 – at the period from 3 to 10 course of RTX). The overall incidence of serious AE was 2.2/100 PY (95% CI 1.4-3.5). The spectrum of severe AE included: pneumonia in 7 pts, infusion reactions in 5, as well as in one case: cerebral ischemia, acute pancreatitis, allergic pneumonitis, lymphoma of pharynx, purulent arthritis, lower limb vein thrombosis, pulmonary embolism of small arteries. The most frequent AE were infections (n=53), with no serious opportunistic infections reported. The overall incidence of all infections was 6.4/100 PY (95% CI 4.9-8.3), serious infections – 1.32/100 PY (95% CI 0.7-2.4). The level of immunoglobulin G during follow-up period decreased from 12.9±4.9 to 10.1±3.4g/l (p=0.0001), but remained within normal limits. Infusion reactions occurred in 15 pts (1.8/100 PY, 95% CI 1-3). Other AE were observed in 9 pts (6%) (1.1/100 PY, 95% CI 0.53-2.12). Sixteen deaths were recorded – 10.7% or 1.91/100 PY, 95% CI 1.2-3.1. In most cases, pts died from the progression of the major organ failure. The causes of death were: progression of the interstitial lung disease (ILD) in 4 pts, heart failure associated with SSc cardiomyopathy (2), renal crisis (4), pulmonary arterial hypertension and ILD (2), pneumonia (2), sepsis after tooth extraction (1), acute pulmonary embolism (1).

Conclusion: In our study, we considered the overall safety profile of RTX in SSc as favorable. It was similar to the AE profile in other autoimmune diseases treated with RTX. With an increase of the cumulative dose of RTX, there was no increase in AE. RTX could be considered as a relatively safe drug for the complex therapy of SSc when standard therapy is ineffective or impossible.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2021-eular.1325

AB0424 NUTRIENT DEFICIENCIES IN SYSTEMIC SCLEROSIS: A SYSTEMATIC REVIEW
A. Nguyen1, Z. McMahan2, E. Volkmann3. 1David Geffen School of Medicine at UCLA, Medicine, Los Angeles, United States of America; 2Johns Hopkins University School of Medicine, Medicine - Rheumatology, Baltimore, United States of America; 3David Geffen School of Medicine at UCLA, Medicine - Rheumatology, Los Angeles, United States of America

Background: Malnutrition is a critical concern in patients with systemic sclerosis (SSc). However, the extent and types of nutrient deficiencies in SSc remain unclear.

Objectives: 1) To identify the nutrient deficiencies commonly reported in SSc; 2) To evaluate associations between specific nutrient deficiencies and SSc subtype and clinical manifestations.

Methods: We conducted a systematic review of all published reports on SSc and nutrition in PubMed from its inception to August 2020. Clinical trials, observational studies, and case series (with ≥20 cases) containing data on nutritional deficiency and SSc were included. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for reporting our findings. Two reviewers (ADN and ERV) studied the titles and abstracts of all search results. Studies that found significant correlation were included for detailed analysis.

Results: Among 790 retrieved publications, 35 full-length articles and 3 abstracts met the inclusion criteria. Included studies took place across multiple geographic locations and included patients with both diffuse and limited cutaneous SSc. Vitamin D deficiency was the most commonly reported deficiency described in SSc, followed by vitamin B12, folate, selenium, zinc, and iron (Table 1). In addition, some small studies found deficiencies in thiamine, pyridoxine, alpha-tocopherol, and carotene. Intestinal lung disease was associated with vitamin D deficiency and elevated homocysteine (Hcy), while pulmonary hypertension was associated with elevated Hcy. Vitamin D deficiency was also associated with increased modified Rodman skin score (mRSS) and increased risk of SSc-related organ involvement.

Conclusion: Nutrient deficiencies are common in SSc and are associated with specific SSc features. Routine screening for nutrient deficiencies may lead to early detection of malnutrition. Future studies are needed to understand how nutritional interventions affect patient outcomes in SSc.

REFERENCES: